Robert Vescio

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 842 citations

Hematological Malignancy, Oncology, Daratumumab Monotherapy +6

Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution

Daniel C. Douek, Robert Vescio, Michael R. Betts et al. · The Lancet · 2000 · 575 citations

Cell Therapy, Transplantation, Marrow Transplantation +10

Kaposi's Sarcoma-Associated Herpesvirus Infection of Bone Marrow Dendritic Cells from Multiple Myeloma Patients

Matthew B. Rettig, Huffman K.J., Robert Vescio et al. · Science · 1997 · 480 citations

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Hans Mark, Hank H. Yang, Kimberly M. Parker et al. · PubMed · 2003 · 418 citations

Chemotherapeutic Agents, Tumor Biology, Hematological Malignancy +11

Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases

Tianling Chen, James R. Berenson, Robert Vescio et al. · The Journal of Clinical Pharmacology · 2002 · 369 citations